213 related articles for article (PubMed ID: 32430981)
41. A Fluorinated Supramolecular Self-Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy.
Jia S; Ji S; Zhao J; Lv Y; Wang J; Sun D; Ding D
Small Methods; 2023 May; 7(5):e2201409. PubMed ID: 36802205
[TBL] [Abstract][Full Text] [Related]
42. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
43. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
[TBL] [Abstract][Full Text] [Related]
44. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
[TBL] [Abstract][Full Text] [Related]
45. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
[TBL] [Abstract][Full Text] [Related]
46. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
[TBL] [Abstract][Full Text] [Related]
47. A Personalized Cancer Nanovaccine that Enhances T-Cell Responses and Efficacy Through Dual Interactions with Dendritic Cells and T Cells.
Go S; Jung M; Lee S; Moon S; Hong J; Kim C; Chung Y; Kim BS
Adv Mater; 2023 Dec; 35(49):e2303979. PubMed ID: 37515819
[TBL] [Abstract][Full Text] [Related]
48. Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.
Xie X; Feng Y; Zhang H; Su Q; Song T; Yang G; Li N; Wei X; Li T; Qin X; Li S; Wu C; Zhang X; Wang G; Liu Y; Yang H
Bioact Mater; 2022 Oct; 16():107-119. PubMed ID: 35386322
[TBL] [Abstract][Full Text] [Related]
49. Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.
Fontana F; Fusciello M; Groeneveldt C; Capasso C; Chiaro J; Feola S; Liu Z; Mäkilä EM; Salonen JJ; Hirvonen JT; Cerullo V; Santos HA
ACS Nano; 2019 Jun; 13(6):6477-6490. PubMed ID: 31100004
[TBL] [Abstract][Full Text] [Related]
50. In Vivo Imaging Tracking and Immune Responses to Nanovaccines Involving Combined Antigen Nanoparticles with a Programmed Delivery.
Dong X; Liang J; Yang A; Wang C; Kong D; Lv F
ACS Appl Mater Interfaces; 2018 Jul; 10(26):21861-21875. PubMed ID: 29901978
[TBL] [Abstract][Full Text] [Related]
51. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
52. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
53. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
[TBL] [Abstract][Full Text] [Related]
54. Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy.
Xiong X; Zhao J; Pan J; Liu C; Guo X; Zhou S
Nano Lett; 2021 Oct; 21(19):8418-8425. PubMed ID: 34546061
[TBL] [Abstract][Full Text] [Related]
55. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.
Kroll AV; Fang RH; Jiang Y; Zhou J; Wei X; Yu CL; Gao J; Luk BT; Dehaini D; Gao W; Zhang L
Adv Mater; 2017 Dec; 29(47):. PubMed ID: 29239517
[TBL] [Abstract][Full Text] [Related]
56. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
57. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators.
Conniot J; Scomparin A; Peres C; Yeini E; Pozzi S; Matos AI; Kleiner R; Moura LIF; Zupančič E; Viana AS; Doron H; Gois PMP; Erez N; Jung S; Satchi-Fainaro R; Florindo HF
Nat Nanotechnol; 2019 Sep; 14(9):891-901. PubMed ID: 31384037
[TBL] [Abstract][Full Text] [Related]
58. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
59. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
Front Immunol; 2022; 13():799026. PubMed ID: 35273594
[TBL] [Abstract][Full Text] [Related]
60. A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy.
Zhao J; Xu Y; Ma S; Wang Y; Huang Z; Qu H; Yao H; Zhang Y; Wu G; Huang L; Song W; Tang Z; Chen X
Adv Mater; 2022 Mar; 34(10):e2109254. PubMed ID: 34984753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
